MIAMI--(BUSINESS WIRE)--Jan. 24, 2006--Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today provided an update on prescription growth and other matters related to its lead commercialized product, Vivelle-Dot(TM) (estradiol transdermal system), which is marketed and sold by Novogyne Pharmaceuticals, a joint venture between Noven and Novartis Pharmaceuticals Corporation. Total prescriptions for Vivelle-Dot(TM) in 2005 increased 11% compared to 2004. During the same period, the estrogen segment of the U.S. hormone therapy (HT) market decreased 9%. At the end of 2005, Vivelle-Dot(TM) held a 44.6% share of the transdermal estrogen therapy market, up from 40.2% at the end of 2004, and was the most dispensed transdermal estrogen product in the U.S. for the third consecutive year.
